Drug Shortage Report for VIOKACE
Report ID | 191469 |
Drug Identification Number | 02241933 |
Brand name | VIOKACE |
Common or Proper name | Pancrelipase |
Company Name | NESTLE ENTERPRISES S.A. |
Market Status | MARKETED |
Active Ingredient(s) | AMYLASE PROTEASE LIPASE |
Strength(s) | 113400UNIT 112500UNIT 20880UNIT |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 100 tablet bottles |
ATC code | A09AA |
ATC description | DIGESTIVES, INCL ENZYMES |
Reason for shortage | Shortage of an active ingredient. |
Anticipated start date | 2023-05-03 |
Actual start date | 2023-05-04 |
Estimated end date | |
Actual end date | 2023-08-02 |
Shortage status | Resolved |
Updated date | 2023-08-03 |
Company comments | Nestlé Enterprises S.A. are pleased to confirm supply availability has been restored of Viokace 20,880 tablets effective August 2, 2023. There has been no impact on availability of the 10,440 strength. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 12, RUE ENTRE-DEUX-VILLES VEVEY, -- SWITZERLAND 1800 |
Company contact information | kfeltmate@apcipharma.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v17 | 2023-08-03 | English | Compare |
v16 | 2023-08-02 | French | Compare |
v15 | 2023-08-02 | English | Compare |
v14 | 2023-08-02 | English | Compare |
v13 | 2023-05-08 | French | Compare |
v12 | 2023-05-08 | English | Compare |
v11 | 2023-05-05 | English | Compare |
v10 | 2023-05-04 | French | Compare |
v9 | 2023-05-04 | English | Compare |
v8 | 2023-05-04 | English | Compare |
v7 | 2023-05-02 | French | Compare |
v6 | 2023-05-02 | English | Compare |
v5 | 2023-05-02 | French | Compare |
v4 | 2023-05-02 | English | Compare |
v3 | 2023-05-02 | French | Compare |
v2 | 2023-05-02 | French | Compare |
v1 | 2023-05-02 | English | Compare |
Showing 1 to 17 of 17